ANUH PHARMA LTD.
Registered Office : 3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, Mumbai - 400018 INDIA.
Tel. : +91-22-6622 7575 • **Fax :** +91-22-6622 7600 / 7500
Email : anuh@sk1932.com • **CIN :** L24230MH1960PLC011586
Web: www.anuhpharma.com

Date: 06th November, 2026

To,
The Manager (Listing)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400001
BSE Symbol: ANUHPHR
BSE Scrip Code: 506260

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra-Kurla Complex,
Bandra (E), Mumbai – 400051
NSE Symbol: ANUHPHR; Series: EQ

Sub: Investor Presentation – Q2 and H1 FY 2026-27.

Dear Sir/Madam,

With reference to the subject mentioned above and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Investor Presentation for Q2 and H1 FY 2026-27.

This intimation is also being uploaded on the Company's website at www.anuhpharma.com.

Kindly take the above on your records.

Thanking you,

Yours faithfully,

FOR ANUH PHARMA LIMITED

MANAN JAYESH VADHAN
Digitally signed by MANAN JAYESH VADHAN
Date: 2026.11.06 14:51:48 +05'30'

MANAN VADHAN
COMPANY SECRETARY & COMPLIANCE OFFICER

Encl: As above

ANUH PHARMA LTD.

Investor Presentation

H1 FY27 | November 2026



BSE - 506260, NSE- ANUHPHR
Bloomberg: ANUH IN | Reuters: ANUH.BO
www.anuhpharma.com

Safe Harbour Statement

- This presentation may include certain "forward looking statements", based on current expectations, within the meaning of applicable laws and regulations.
- Actual results may differ and the Company does not guarantee realization of these statements. The Company also disclaims any obligation to revise any forward-looking statements.
- The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.
- No part of this presentation may be reproduced, quoted or circulated without prior written approval from Anuh Pharma Limited.

Table of Contents

01 H1 FY27 & H1 FY 26 Performance

02 Company Overview

03 Infrastructure

04 Future Outlook

05 Corporate Social Responsibility



01

H1 FY27 & H1 FY26 Performance

H1 FY27 & H1 FY 26 at a Glance

Rs. in Crores

Operating Revenue

379.05

+1.80% YoY

Rs. 372.36 Cr in H1 FY26

Operating Profit

78.11

+26.23% YoY

20.61% margin vs 16.62% LY

EBITDA

36.92

+39.11% YoY

9.74% margin vs 7.13% LY

Profit Before Tax

31.98

+53.19% YoY

8.44% margin vs 5.60% LY

PAT

22.64

+42.25% YoY

5.97% margin vs 4.27% LY

ROCE

16.52%

+60 bps vs FY26

FY26: 15.92%

EPS (Rs.)

2.26

+42.06% YoY

H1 FY26: Rs. 1.59

Production (MT)

987 MT

+15.31% YoY

H1 FY26: 856 MT

Message from the Joint Managing Directors – H1 FY27

Dear Shareholders, Investors and Partners,

In H1 FY27 we chose margin over volume. Revenue was broadly flat at Rs. 379 Cr, while PAT rose 42% and EBITDA margin improved by 261 bps to 9.7%.

Higher-value products replaced lower-margin volumes, and domestic demand offset softer exports. Production grew 15%, and ROCE reached 16.5%.

With our new Tarapur unit commissioned, capacity of 2,975 MTPA our H2 priority is to rebuild exports and deliver 15–20% annual growth.

We thank you for your continued trust and support.

Ritesh Shah, Joint MD | Vivek Shah, Joint MD

H1 FY27 – PROFITABILITY

Revenue (Cr)	**379.05**	**+1.80%**
EBITDA (Cr)	**36.92**	**+39.11%**
PAT (Cr)	**22.64**	**+42.25%**

H1 FY27 – OPERATIONS & RETURNS

Production (MT)	**987**	**+15.31%**
PBT (Cr)	**31.98**	**+53.19%**
ROCE	**16.52%**	**+60 bps**

H1 FY27 Financial Performance


Rs. in Crores


Financial Highlights	Q2 FY27	Q1 FY27	% QoQ	H1 FY27	H1 FY26	% YoY
Operating Revenue	185.24	193.81	**(4.42)**	379.05	372.36	**1.80**
Operating Profit *	39.96	38.15	**4.75**	78.11	61.87	**26.23**
% of Margin	*21.57*	*19.68*		*20.61*	*16.62*	
Other Income	0.61	3.08	**(80.23)**	3.69	4.37	**(15.61)**
EBITDA	**17.55**	**19.36**	**(9.36)**	**36.92**	**26.54**	**39.11**
% of Margin	*9.47*	*9.99*		*9.74*	*7.13*	
Interest	0.05	0.00	**1,381.29**	0.06	0.29	**(80.71)**
Depreciation	2.45	2.43	**0.78**	4.88	5.38	**(9.15)**
PBT	15.05	16.93	**(11.11)**	31.98	20.87	**53.19**
TAX	3.83	5.50	**(30.32)**	9.34	4.96	**88.26**
PAT	**11.21**	**11.42**	**(1.85)**	**22.64**	**15.91**	**42.25**
Reported EPS (Rs.)	1.12	1.14	**(1.86)**	2.26	1.59	**42.06**


* Operating Profit = PBT + Depreciation + Other Expenses - Other Income. Figures in brackets denote decline.

Five-Year Financial Track Record

Rs. in Crores | FY22 - FY26











Balance Sheet Strength & Shareholder Returns

FY22 - FY26











FY26 dividend as proposed.

Revenue Mix & Customer Concentration


H1 FY27 vs H1 FY26






Export Revenue by Geography


% of export sales





Product Mix - H1 FY27 vs H1 FY26

Rs. in Crores





02

Company Overview

Anuh Pharma at a Glance

API manufacturer since 1989

~46%
of FY26 revenue from exports

360
marketing partners / customers

72+
countries served

3
facilities - 2 at Tarapur, 1 at Mahape

Business Profile

- One of the largest manufacturers of Macrolides and Anti-TB products in India.
- Major player in Anti-bacterials, Anti-malarial, Anti-hypertension and Corticosteroids.
- Strong marketing partnerships with 360 customers in over 72 countries, including Europe, Mexico and South Africa.
- The Company derived ~46% of its revenues from exports in FY26.

Infrastructure & Group

- Two manufacturing facilities at Tarapur; **the new facility is spread over 9,520 sq. mtrs of land.**
- R&D facility at Mahape spread over 10,000 sq. ft.
- Part of the INR 8.5 bn SK Group, employing ~2,200 people across pharma formulations, trading, distribution and logistics.

Journey So Far

1989 - 2026

FOUNDATION 1989 - 2010

1989 Started manufacturing Erythromycin salts with capacity of 150 MTPA.

1995 Doubled the capacity to 300 MTPA.

2002 Received WHO-GMP for its facilities.

2006 New plot of 1,800 SQMT; output capacity expanded to 600 MTPA.

2010 COS and EU/GMP approval for Erythromycin, Erythromycin Ethyl Succinate and Pyrazinamide.

GLOBAL APPROVALS 2012 - 2019

2012 Acquired R&D assets of Invent Pharma (Spain); DSIR approval.

2014 COFEPRIS Mexico approval for three Erythromycin salts.

2015 COFEPRIS Mexico for Chloramphenicol & Palmitate; WHO pre-qualification for Sulphadoxine.

2017 DMF approval from UK MHRA for Erythromycin Stearate.

2018 Certificate of GMP (WHO GMP) from FDA Maharashtra.

2019 WHO pre-qualification for Pyrazinamide & Sulphadoxine; EU GMP from AEMPS Spain.

2019 New 7,800 SQMT plot (+600 MTPA); USFDA inspection passed, zero 483 observations.

SCALE & GROWTH 2020 - 2026

2020 WHO Geneva pre-qualification for Pyrimethamine API.

2023 CEP from EDQM for Sulphadoxine, Azithromycin & Gliclazide; capacity to 1,800 MTPA.

2024 WHO pre-qualification for Isoniazid plus renewals; CEP for Allopurinol & Ambroxol HCL.

2024 Capacity 1,800 to 2,200 MTPA; got listed on NSE.

2025 Capacity 2,200 to 2,400 MTPA; CEP from EDQM for Sulfadimethoxine.

2026 USFDA inspection completed successfully with zero 483 observations.

2026 WHO pre-qualification for Amodiaquine HCL; awarded EcoVadis Bronze Medal.

2026 New 9,520 SQMT facility at Tarapur; 3 facilities in total.

Competitive Advantage

Market Leadership

Products where Anuh holds a leading position

- **Erythromycin salts**
- **Pyrazinamide**
- **Sulfadoxine**
- **Ambroxol HCL**
- **Gliclazide**
- **Clobetasol Propionate**
- **Betamethasone Dipropionate**

Why Customers Choose Anuh

Regulatory approvals
USFDA, EU GMP, WHO-GMP, EDQM CEPs and WHO Geneva pre-qualifications across the portfolio.

Environmental, health and safety compliance
Audited and approved by multinational companies.

Well diversified sourcing
Backward integration in key products.

Surplus capacity available
Headroom to service incremental regulated-market demand.

Financially strong
Net Debt-free balance sheet with a consistent dividend record.

Strong R&D capabilities
DSIR-approved R&D centre driving process innovation and new APIs.

Product Portfolio

12 therapeutic categories

MACROLIDES

Erythromycin 11,12 Carbonate · Erythromycin Base · Erythromycin Estolate · Erythromycin Propionate · Erythromycin Ethyl Succinate · Erythromycin Phosphate · Erythromycin Stearate

CORTICOSTEROIDS

Beclomethasone Dipropionate · Betamethasone Acetate · Betamethasone Dipropionate · Betamethasone Sodium Phosphate · Betamethasone Valerate · Clobetasol Propionate · Deflazacort · Dexamethasone Sodium Phosphate · Dexamethasone Acetate · Mometasone Furoate · Prednisolone Acetate · Prednisolone Sodium Phosphate · Triamcinolone Acetonide · Triamcinolone Base · Methyl Prednisolone

HIGHER MACROLIDES

Azithromycin

ANTI ASTHAMATICS

Acebrophylline

ANTI HISTAMINE

Bilsatin

EXPECTORANT

Ambroxol HCL · Acefylline Piperazine

ANTI TB

Pyrazinamide · Isoniazid

ANTI DIABETIC

Gliclazide · Vildagliptin · Dapagliflozin

ANTI MALARIAL

Sulfadoxine · Pyrimethamine · Amodiquine

QUINOLONES

Moxifloxacin

ANTI BACTERIAL

Chloramphenicol · Chloramphenicol Palmitate

ANTIBIOTIC

Sulfadimethoxine

ANTI GOUT

Allopurinol

Board & Senior Management

Board of Directors

Mr. Arun Todarwal / Chairman

Fellow member of the ICAI, in practice since 1981. Has been a director of several large listed corporations in India, serving on Audit, Risk, NRC and ESG/CSR Committees.

Mr. Bipin N Shah / Vice Chairman

Involved with Anuh Pharma since inception as Managing Director. Bachelor's degree in Chemical Engineering; President of the Thane Belapur Industries Association.

Mr. Ritesh B Shah / Joint MD

BSc Chemistry, MBA. Handled international marketing for Anuh Pharma for over 20 years; currently involved in overall management of the Company.

Mr. Vivek B Shah / Joint MD

MSc Biotechnology. Handling the entire manufacturing operations and R&D since 2009.

Senior Management

Mr. Raju Kotadia / CMO - EM

BSc Chemistry; part of Anuh Pharma since inception, handling overall sales management.

Mr. Vinayak Shenoy / CMO - MM

MBA Marketing, 15+ years in APIs and intermediates across USA, Europe, CIS, SEA, LATAM and India.

Mr. P.N. Rao / GM Quality

M Tech in QMS, Black belt six Sigma with 27+ Years of Experience in Pharma Quality management

Mr. Darshan Rampariya / CFO

CA with 18+ years in audit, taxation, finance and investor relations.

Mr. Manan Vadhan / CS & Compliance Officer

ACS with 5+ years in corporate secretarial compliance, corporate actions and SEBI LODR.

Dr. Sanjay Vaidya / GM R&D

25 years of industrial process research experience in API molecules.


Mr. Gulshan Sharma / GM Works

B.Tech (Chemical and Pharmaceutical) with 21+ years in API and food industries.

Shareholding Pattern

As on 30th October 2026

Ownership Structure



Promoter & Promoter Group

71.80%

Public

28.20%

Market Capitalisation

INR 877 Cr.

Free Float Market Cap.

INR 247 Cr.



03

Infrastructure

State of the Art Manufacturing Facility

Tarapur, Maharashtra

20,920	11	3	2,975
sq. meters site area	API blocks	intermediate blocks	MTPA total capacity

USD FDA / EU GMP / WHO Pre-qualified Site

Anuh Pharma has an US FDA, EU GMP, WHO pre-qualified approved manufacturing facility at Tarapur spread across 20,920 sq. meters with 11 API blocks and 3 intermediate blocks, with total capacity of 2,975 MTPA -this includes the new expanded capacity.

With the commissioning of Zero Liquid Discharge (ZLD), the Company stands with a huge compliance advantage, keeping environmental challenges in mind.

Visit-https://www.anuhpharma.com/manufacturing.html for more details

Other Facilities

- Zero Liquid Discharge effluent control system treating 100% of generated pollution.
- Green belt provided to reduce the carbon footprint.
- 100% power backup via a dedicated power line from the power distributor to our premises.
- Entire facility equipped with the latest fire fighting and safety measures.
- Adjoining office and a training hall for staff.

New Site: Tarapur Unit F-10

MIDC Tarapur, Boisar

New site details

Inaugurated on 20 October 2026, Tarapur Unit F-10 sits in the same MIDC Tarapur industrial area at Boisar as Tarapur Unit E-17 & E-18. A modern, multi-storey cGMP facility designed for multi-purpose API manufacturing, it adds dedicated production, quality-control and warehousing capacity to Anuh Pharma's network — and is being integrated into our group-wide quality management system.

- Multi-purpose cGMP API manufacturing
- 575 MTPA installed capacity
- ~69 KL total reactor capacity
- 2 API Blocks & 1 Intermediate Block
- ~9,500 m^2 site with a multi-storey production block
- Stainless-steel & glass-lined reactors (up to 6.3 KL)
- Centrifuges, ANFD, fluid-bed, rotocone & tray dryers
- In-house QC & microbiology — HPLC, GC/GC-HS, TOC, FTIR & stability chambers, all server-connected
- Purified water to IP / BP / EP / USP
- Zero-liquid-discharge effluent treatment (ETP + RO)
- Advanced solvent recovery
- Dedicated finished-goods warehouse

Inside the Tarapur Facility





Manufacturing Facility



Inside the Plant

EU GMP / WHO pre-qualified operations









Clean-room corridors, reactor halls and finished-goods warehousing at Tarapur.

F-10/1 New Plant

Plot F-10/1, MIDC Tarapur



Main gate



Plant building

Main gate and plant building at the new F-10/1 site.

F-10/1 New Plant

Utilities and quality control



Boiler house



QC laboratory

Boiler house and QC laboratory at the new F-10/1 site.

Dedicated Research & Development Facility

Mahape, Navi Mumbai

10,000
sq. ft. R&D facility at Mahape

DSIR
approved R&D centre

2012
acquired R&D assets of Invent Pharma, Spain



ANALYTICAL DEVELOPMENT

Facilitate activities that lead to characterization and profiling of products.



CHEMICAL SYNTHESIS

Develop processes and products.



PILOT PLANT

Lab scale reaction batches to validate research.



04

Future Outlook

Future Outlook - Growth Strategy

Growth Levers

- Extensive volume expansions across our API lines, coupled with high-value regulated market growth.
- Continued priority on process innovation and cost optimisation.
- Strategic market diversification focusing on exports to reduce currency risk.
- Continued investments in compliance, operational efficiency and capacity enhancement.
- Diversified product portfolio and improving operational leverage.

15-20% **per annum steady growth rate anticipated by the Company.**

Products Under Development

01 Bisoprolol Fumarate
Beta Blocker/Anti Hypertension

02 Brivaracetam
Anticonvulsant/Antiepileptic

03 Tegoprazan Fumarate
Gastrointestinal Agent



05

Corporate Social Responsibility

Corporate Social Responsibility

Servicing society for a better tomorrow

Chhatrapati Shikshan Mandal

Building of a toilet block for about 3,200 students of the school.

Indian Development Foundation

Project Aashayein - education for underprivileged children.

Churchgate Lions Service Funds

Promoting sports for specially challenged children.

Greensole Foundation

Recycled footwear and masks for needy children.

Indian Development Foundation

Project Dignity - menstrual hygiene kits and sanitary pads for needy girl children.

Late Shri Kantilal Manilal Sonawala Charitable Trust

Education and accommodation for needy girls.

Thank You

For specific queries, please feel free to contact:

Mr. Darshan Rampariya
Chief Financial Officer
darshan.r@anuhpharma.com

Anuh Pharma Ltd.
www.anuhpharma.com
BSE: 506260, NSE: ANUHPHR